Home > Boards > US Listed > Biotechs > Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics, which is developing peptide-based oral drugs

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
protagonist12 Member Profile
 
Followed By 55
Posts 1,845
Boards Moderated 1
Alias Born 11/14/12
160x600 placeholder
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera PR Newswire (US) - 10/21/2020 7:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 10/2/2020 5:14:48 PM
Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020 PR Newswire (US) - 9/17/2020 4:30:00 PM
Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire (US) - 9/15/2020 4:48:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2020 4:33:39 PM
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference PR Newswire (US) - 9/10/2020 4:30:00 PM
Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar PR Newswire (US) - 9/2/2020 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/18/2020 5:34:10 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/18/2020 5:05:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2020 4:35:09 PM
Protagonist Appoints Sarah O'Dowd to Board of Directors PR Newswire (US) - 8/13/2020 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2020 5:39:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 4:09:34 PM
Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update PR Newswire (US) - 8/6/2020 4:01:00 PM
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera PR Newswire (US) - 6/17/2020 11:07:00 PM
Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference PR Newswire (US) - 6/16/2020 6:05:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 6/9/2020 4:33:59 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/8/2020 4:05:46 PM
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress PR Newswire (US) - 6/4/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:21:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:20:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:19:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:17:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:16:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:13:03 PM
protagonist12   Thursday, 08/25/16 02:45:37 PM
Re: None
Post # of 28 
Protagonist Therapeutics, which is developing peptide-based oral drugs for inflammatory bowel disease, raised $90 million by offering 7.5 million shares at $12, within the range of $11 to $13. The company had originally planned to raise $70 million by offering 5.84 million shares. Insiders had indicated on buying up to $40 million of the IPO. Protagonist Therapeutics plans to list on the Nasdaq under the symbol PTGX. Leerink Partners, Barclays and BMO Capital Markets acted as lead managers on the deal.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences